Plasma phospholipids profiling changes were associated with the therapeutic response to Roxadustat in peritoneal dialysis patients
Background: Elevated Phospholipids (PLs) and sphingolipid (SM) metabolism relates to with poor clinical status and adverse outcome of end-stage kidney disease patients undergoing peritoneal dialysis (PD). Studies have suggested that the use of hypoxia-inducible factor prolyl hydroxylase inhibitor (H...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Physiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphys.2023.1279578/full |
| _version_ | 1827580939342970880 |
|---|---|
| author | Ya-Hui Yang Yishakejiang Saimaiti Yishakejiang Saimaiti Yang Zhao Wen Tang |
| author_facet | Ya-Hui Yang Yishakejiang Saimaiti Yishakejiang Saimaiti Yang Zhao Wen Tang |
| author_sort | Ya-Hui Yang |
| collection | DOAJ |
| description | Background: Elevated Phospholipids (PLs) and sphingolipid (SM) metabolism relates to with poor clinical status and adverse outcome of end-stage kidney disease patients undergoing peritoneal dialysis (PD). Studies have suggested that the use of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) (Roxadustat) is associated with altered lipid metabolism. Observing on how PLs and SMs changes after the HIF-PHI treatment in PD patients may help understand the possible effect of HIF-PHI on PD patients besides correcting of anemia.Materials and methods: Stable peritoneal dialysis (PD) patients treated with Roxadustat for over 3 months were included. Phospholipid and sphingolipid metabolism were measured before and after treatment.Results: 25 PD patients were included. Overall, phospholipid and sphingolipid metabolism showed a decreasing trend after HIF-PHI treatment. Levels of LysoPC (20:0), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine [CisPC (DLPC) (18:2)], lysophosphatidylethanolamine (LysoPE) (14:0), and sphingomyelin (d18:1/17:0) (17:0) were significantly decreased (all p < 0.05). Further regression analyses confirmed the significant relationship between the increased of hemoglobin levels and the decrease in egg lyso PC: phosphatidylethanolamines (PE) (16:0–18:1), PE (16:0–18:2), PE (16:0–22:6), PE (18:0–20:4), PE (18:0–18:2), LysoPE (18:0), LysoPE (18:1), and phosphatidylcholine (PC) (18:1–18:0).Conclusion: This study demonstrated that phospholipid and sphingolipid metabolism decreased after administration of HIF-PHI and was associated with improvement of anemia. |
| first_indexed | 2024-03-08T22:28:18Z |
| format | Article |
| id | doaj.art-5f4c1b34744f4c64a99b007f1eb9a1f3 |
| institution | Directory Open Access Journal |
| issn | 1664-042X |
| language | English |
| last_indexed | 2024-03-08T22:28:18Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Physiology |
| spelling | doaj.art-5f4c1b34744f4c64a99b007f1eb9a1f32023-12-18T07:40:01ZengFrontiers Media S.A.Frontiers in Physiology1664-042X2023-12-011410.3389/fphys.2023.12795781279578Plasma phospholipids profiling changes were associated with the therapeutic response to Roxadustat in peritoneal dialysis patientsYa-Hui Yang0Yishakejiang Saimaiti1Yishakejiang Saimaiti2Yang Zhao3Wen Tang4Department of Nephrology, Peking University Third Hospital, Beijing, ChinaDepartment of Nephrology, Peking University Third Hospital, Beijing, ChinaDepartment of Laboratory Medicine, Peking University Third Hospital, Beijing, ChinaDepartment of Laboratory Medicine, Peking University Third Hospital, Beijing, ChinaDepartment of Nephrology, Peking University Third Hospital, Beijing, ChinaBackground: Elevated Phospholipids (PLs) and sphingolipid (SM) metabolism relates to with poor clinical status and adverse outcome of end-stage kidney disease patients undergoing peritoneal dialysis (PD). Studies have suggested that the use of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) (Roxadustat) is associated with altered lipid metabolism. Observing on how PLs and SMs changes after the HIF-PHI treatment in PD patients may help understand the possible effect of HIF-PHI on PD patients besides correcting of anemia.Materials and methods: Stable peritoneal dialysis (PD) patients treated with Roxadustat for over 3 months were included. Phospholipid and sphingolipid metabolism were measured before and after treatment.Results: 25 PD patients were included. Overall, phospholipid and sphingolipid metabolism showed a decreasing trend after HIF-PHI treatment. Levels of LysoPC (20:0), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine [CisPC (DLPC) (18:2)], lysophosphatidylethanolamine (LysoPE) (14:0), and sphingomyelin (d18:1/17:0) (17:0) were significantly decreased (all p < 0.05). Further regression analyses confirmed the significant relationship between the increased of hemoglobin levels and the decrease in egg lyso PC: phosphatidylethanolamines (PE) (16:0–18:1), PE (16:0–18:2), PE (16:0–22:6), PE (18:0–20:4), PE (18:0–18:2), LysoPE (18:0), LysoPE (18:1), and phosphatidylcholine (PC) (18:1–18:0).Conclusion: This study demonstrated that phospholipid and sphingolipid metabolism decreased after administration of HIF-PHI and was associated with improvement of anemia.https://www.frontiersin.org/articles/10.3389/fphys.2023.1279578/fullperitoneal dialysisphospholipidshypoxia inducible factor prolyl hydroxylase inhibitorsanemiaend-stage kidney disease |
| spellingShingle | Ya-Hui Yang Yishakejiang Saimaiti Yishakejiang Saimaiti Yang Zhao Wen Tang Plasma phospholipids profiling changes were associated with the therapeutic response to Roxadustat in peritoneal dialysis patients Frontiers in Physiology peritoneal dialysis phospholipids hypoxia inducible factor prolyl hydroxylase inhibitors anemia end-stage kidney disease |
| title | Plasma phospholipids profiling changes were associated with the therapeutic response to Roxadustat in peritoneal dialysis patients |
| title_full | Plasma phospholipids profiling changes were associated with the therapeutic response to Roxadustat in peritoneal dialysis patients |
| title_fullStr | Plasma phospholipids profiling changes were associated with the therapeutic response to Roxadustat in peritoneal dialysis patients |
| title_full_unstemmed | Plasma phospholipids profiling changes were associated with the therapeutic response to Roxadustat in peritoneal dialysis patients |
| title_short | Plasma phospholipids profiling changes were associated with the therapeutic response to Roxadustat in peritoneal dialysis patients |
| title_sort | plasma phospholipids profiling changes were associated with the therapeutic response to roxadustat in peritoneal dialysis patients |
| topic | peritoneal dialysis phospholipids hypoxia inducible factor prolyl hydroxylase inhibitors anemia end-stage kidney disease |
| url | https://www.frontiersin.org/articles/10.3389/fphys.2023.1279578/full |
| work_keys_str_mv | AT yahuiyang plasmaphospholipidsprofilingchangeswereassociatedwiththetherapeuticresponsetoroxadustatinperitonealdialysispatients AT yishakejiangsaimaiti plasmaphospholipidsprofilingchangeswereassociatedwiththetherapeuticresponsetoroxadustatinperitonealdialysispatients AT yishakejiangsaimaiti plasmaphospholipidsprofilingchangeswereassociatedwiththetherapeuticresponsetoroxadustatinperitonealdialysispatients AT yangzhao plasmaphospholipidsprofilingchangeswereassociatedwiththetherapeuticresponsetoroxadustatinperitonealdialysispatients AT wentang plasmaphospholipidsprofilingchangeswereassociatedwiththetherapeuticresponsetoroxadustatinperitonealdialysispatients |